NEWS

January 12, 2018 | News

TARA Presents at 2018 Keystone Symposia Heart Failure Conference

January 12, 2018. TARA will present a poster at Keystone Symposia’s “Heart Failure: Crossing the Translational Divide” conference, on January 15. Meet us there to learn about Biowire™ II, our human stem cell-derived “heart-on-a-chip” cardiac tissue platform.

show more

January 12, 2018. TARA will present a poster at Keystone Symposia’s “Heart Failure: Crossing the Translational Divide” conference, on January 15. Meet us there to learn about Biowire™ II, our human stem cell-derived “heart-on-a-chip” cardiac tissue platform. (more…)

show less
October 16, 2017 | News

TARA Biosystems Raises $9 Million Series A Financing

October 16, 2017. NEW YORK, (Newswire.com) – TARA Biosystems announced today that it closed on a $9 million Series A financing. TARA offers testing services on its human stem cell-derived cardiac tissue platform. The company’s platform, which is based on its proprietary Biowire™ technology, enables discovery efforts for novel heart …

show more

October 16, 2017. NEW YORK, (Newswire.com) –

TARA Biosystems announced today that it closed on a $9 million Series A financing.

TARA offers testing services on its human stem cell-derived cardiac tissue platform. The company’s platform, which is based on its proprietary Biowire™ technology, enables discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities.  TARA can also utilize its precision cardiology efforts to help successfully translate research efforts to the clinic.

Series A Proceeds will Fuel 2018 Product Launch and New Product Development

Proceeds from the $9M Series A financing will fuel the launch of TARA’s first products in 2018 and accelerate the development of TARA’s growing portfolio of healthy cardiac tissues, cardiac disease models as well as a range of acute and chronic testing service products.

The Series A round was co-led by Trancos Ventures and Morgan Noble.  “The team has invested considerable effort digging deep into customer needs and, in parallel on the technical front, has generated a significant dataset, supporting a unique and compelling value proposition for the cardiovascular R&D community,” said Craig Asher, the managing partner for Trancos Ventures. “We’ve been further impressed with TARA’s ability to translate these efforts into early traction with big pharma in cardiac toxicology.” The NYS Innovation Venture Capital Fund administered by Empire State Development joined the round, which also included TARA’s existing investors, Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. (NYSE:ARE), 180 Degree Capital Corp. (NASDAQ:TURN; f/k/a Harris & Harris Group, Inc.), Empire State Development’s Innovate NY Fund and the Partnership Fund for New York City.

“TARA is extremely fortunate to be working with this group of highly successful and experienced life science technology investors,” said Misti Ushio, CEO of TARA Biosystems, “This financing will propel the launch of our cardiac analysis solutions based on our Biowire™ technology platform.”

Read more

show less
September 19, 2017 | News

TARA Presents at 2017 SPS Conference in Berlin

September 20, 2017. TARA will present at the 2017 Safety Pharmacology Society (SPS) conference in Berlin from September 24 – 27. Meet us there to learn about Biowire™ II, our human stem cell-derived “heart-on-a-chip” cardiac tissue platform. Biowire™ II enables precision cardiology efforts for novel heart medicines via its disease …

show more

September 20, 2017. TARA will present at the 2017 Safety Pharmacology Society (SPS) conference in Berlin from September 24 – 27. Meet us there to learn about Biowire™ II, our human stem cell-derived “heart-on-a-chip” cardiac tissue platform. Biowire™ II enables precision cardiology efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities. Come see poster #172 or visit us at booth #302 in the Exhibit Hall, Maritim Hotel Berlin.

show less
September 18, 2017 | News

TARA Founder Uses Biowire™ and Neural Networks for Screening

September 18, 2017. Dr. Milica Radisic’s lab at the University of Toronto just published a paper on using Biowire™ technology to screen kinase inhibitors. Kinase inhibitors are cancer targeting drugs, though certain ones have been identified to have cardiotoxic effects. The Radisic lab tested a set of compounds on a …

show more

September 18, 2017. Dr. Milica Radisic’s lab at the University of Toronto just published a paper on using Biowire™ technology to screen kinase inhibitors. Kinase inhibitors are cancer targeting drugs, though certain ones have been identified to have cardiotoxic effects. The Radisic lab tested a set of compounds on a 2D screening assay, used an artificial neural network to select kinase inhibitors of specific interest, and then tested the selected compounds on 3D Biowire™ tissues. The research is published in Scientific Reports.

show less
September 7, 2017 | News

TARA Founder Named Fellow of the Royal Society of Canada

September 7, 2017. Dr. Milica Radisic, a TARA scientific founder, has been named a Fellow of the Royal Society of Canada (RSC). She was inducted based on her global leadership in field of cardiac tissue engineering. Election to the RSC is one of the highest honors a Canadian scholar can …

show more

September 7, 2017. Dr. Milica Radisic, a TARA scientific founder, has been named a Fellow of the Royal Society of Canada (RSC). She was inducted based on her global leadership in field of cardiac tissue engineering. Election to the RSC is one of the highest honors a Canadian scholar can receive. The RSC’s mission is to promote learning and research in the arts, humanities, and sciences.

show less
August 22, 2017 | Press Releases

TARA Appoints Michael P. Graziano as Chief Scientific Officer

August 22, 2017. NEW YORK, (Newswire.com) – TARA Biosystems, Inc., a company developing physiologically relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, announced today that it has appointed pharmaceutical industry leader, Michael P. Graziano, Ph.D., as its Chief Scientific Officer. 

show more

August 22, 2017. NEW YORK, (Newswire.com) –

TARA Biosystems, Inc., a company developing physiologically relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, announced today that it has appointed pharmaceutical industry leader, Michael P. Graziano, Ph.D., as its Chief Scientific Officer. 

(more…)

show less
June 14, 2017 | News

TARA Biosystems Named Red Herring Top 100 of 2017

June 14, 2017. Red Herring has announced the winners of its Top 100 North America 2017 event, held this week in Los Angeles. The winning companies, selected from thousands of prospective startups and tech firms, represent the cutting edge of North America’s world-class technology industry–and demonstrate the region’s continued reputation …

show more

June 14, 2017.

Red Herring has announced the winners of its Top 100 North America 2017 event, held this week in Los Angeles. The winning companies, selected from thousands of prospective startups and tech firms, represent the cutting edge of North America’s world-class technology industry–and demonstrate the region’s continued reputation for digital excellence.

The Top 100 awards were handed out at a special ceremony tonight at the Marina Del Rey Marriott Hotel, where for the past two days companies’ executives have presented their companies to a judging panel comprising industry insiders, analysts and journalists. Entrants also enjoyed a host of keynote speeches and panel discussions featuring some of North America’s top technology leaders.

“This is one of the most innovative and exciting groups of companies we’ve ever hosted at a Top 100 awards show,” said Alex Vieux, chairman of Red Herring. “It’s always a pleasure to come to California and see the cream of North America’s tech crop. 2017 has proven to be another fine year for tech, which is now simply the economy rather than a small part of it.”

Finalist companies operate in all aspects of the tech industry, from fintech and IoT to robotics, security and clean technology. It was a particularly good year for cybersecurity platforms, whose market has diversified and expanded amid technical breakthroughs, and hacks that have made headlines around the world.

“The fact that so many companies here are working at the bleeding edge of tech, goes to show just how fast this sector is moving,” said Vieux. “I’m proud to see so many exciting entrepreneurs at this awards ceremony, and have no doubt they will go on to achieve great things.”

Read More

show less
April 18, 2017 | News

Thirteen startups join Springboard’s Health Innovation Hub

April 18, 2017. A new batch of 13 women-led life science and healthcare startups have been accepted into Springboard Enterprises’ Health Innovation Hub, a year-long program for growth-stage companies preparing to expand and raise funds for new product development.

show more

April 18, 2017. A new batch of 13 women-led life science and healthcare startups have been accepted into Springboard Enterprises’ Health Innovation Hub, a year-long program for growth-stage companies preparing to expand and raise funds for new product development.

(more…)

show less
April 17, 2017 | News

TARA Biosystems Founder Appointed University Professor

April 17, 2017. Gordana Vunjak-Novakovic, PhD, the Mikati Foundation Professor of Biomedical Engineering, professor of medical sciences at P&S, and director of Columbia’s Laboratory for Stem Cells and Tissue Engineering at CUMC, has been appointed a University Professor, Columbia University’s highest academic honor.

show more

April 17, 2017. Gordana Vunjak-Novakovic, PhD, the Mikati Foundation Professor of Biomedical Engineering, professor of medical sciences at P&S, and director of Columbia’s Laboratory for Stem Cells and Tissue Engineering at CUMC, has been appointed a University Professor, Columbia University’s highest academic honor. (more…)

show less
December 7, 2016 | News

New York City's Burgeoning Biotech Industry

December 7, 2016. New buildings on the East Side of Manhattan are signs of life of the city’s foray into a new economy, its burgeoning biotech industry. NY1’s Erin Billups filed the following report. New York is known for many things. The biotech industry is not one of them. But …

show more

December 7, 2016. New buildings on the East Side of Manhattan are signs of life of the city’s foray into a new economy, its burgeoning biotech industry. NY1’s Erin Billups filed the following report.

New York is known for many things. The biotech industry is not one of them. But that is changing.

“Six years ago, there was nothing here. Now, we have over 1,500 people at the center working hand in hand with the academic and medical centers,” says John Cunningham, senior vice president of Alexandria Real Estate Equities.

The new Alexandria Life Sciences Center sits between NYU Langone Medical Center and Bellevue Hospital on East 29th Street, visible from the FDR Drive.

It is the result of a project led by Mayor Michael Bloomberg that broke ground in 2007 to grow the biotech industry around one of America’s most robust academic medical corridors.

“The academic and medical centers in New York produce the greatest amount of medical discoveries and scientific discoveries of any centers in the world,” Cunningham says.

Roche and Eli Lilly are some of the big Pharma names among its 25 tenants. The two 17-story buildings also house startups like Kallyope, the brainchild of three top Columbia University scientists. They are developing therapies around the gut-brain connection.

“We’ve been very fortunate to be able to recruit from many of the great institutions around here, but we’ve also been able to recruit from Copenhagen, United Kingdom, San Francisco, Boston because there are a number of people who just, they like our mission, but they also want to be in New York City,” says Dr. Nancy Thornberry, CEO of Kallyope.

The center’s Launch Labs will rent space for just $1,900 a month and provide grants to potential startups.

Tara Biosystems is a fledgling firm just taking flight with its cardiac tissue technology.

“On our floor alone, there’s at least seven small companies growing and trying to get their companies off the ground, and so there’s a great community of collaboration and help,” siys Misti Ushio, CEO of Tara Biosystems.
read more

show less

Contact

As a result, currently 8 out of 9 drugs tested for cardiotoxicity fail in clinical trials, after spending significant time.

TARA
430 East 29th Street
Suite #1015
New York, NY 10016
USA
info@tarabiosystems.com